Ilene Galinsky

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Pascal Furet, Guido Bold, Arghya Ray, 2008, Blood.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Peter Marynen, Rafeul Alam, Jan Cools, 2003, The New England journal of medicine.

The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.

D. DeAngelo, I. Galinsky, R. Stone, 2005, Cancer research.

Proteomic and genetic approaches identify Syk as an AML target.

Tina N. Davis, Steven A Carr, William C Hahn, 2009, Cancer cell.

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Gabriela Alexe, Giovanni Roti, Nicola Tolliday, 2012, The Journal of clinical investigation.